113 related articles for article (PubMed ID: 12699380)
21. Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.
Mondal C; Halder AK; Adhikari N; Saha A; Saha KD; Gayen S; Jha T
Eur J Med Chem; 2015 Jan; 90():860-75. PubMed ID: 25535952
[TBL] [Abstract][Full Text] [Related]
22. Characterization of afloqualone N-glucuronidation: species differences and identification of human UDP-glucuronosyltransferase isoform(s).
Kaji H; Kume T
Drug Metab Dispos; 2005 Jan; 33(1):60-7. PubMed ID: 15475412
[TBL] [Abstract][Full Text] [Related]
23. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
24. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.
Ekins S; Bravi G; Wikel JH; Wrighton SA
J Pharmacol Exp Ther; 1999 Oct; 291(1):424-33. PubMed ID: 10490933
[TBL] [Abstract][Full Text] [Related]
25. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
26. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
27. Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors.
Wei HY; Chen GJ; Chen CL; Lin TH
J Mol Model; 2012 Feb; 18(2):675-92. PubMed ID: 21562827
[TBL] [Abstract][Full Text] [Related]
28. Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes.
Yamanaka H; Nakajima M; Katoh M; Kanoh A; Tamura O; Ishibashi H; Yokoi T
Drug Metab Dispos; 2005 Jan; 33(1):23-30. PubMed ID: 15470160
[TBL] [Abstract][Full Text] [Related]
29. QSAR and Pharmacophore Mapping Studies on Benzothiazinimines to Relate their Structural Features with anti-HIV Activity.
Geethaavacini G; Poh GP; Yan LY; Deepashini R; Shalini S; Harish R; Sureshkumar K; Ravichandran V
Med Chem; 2018; 14(7):733-740. PubMed ID: 29807521
[TBL] [Abstract][Full Text] [Related]
30. Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists.
Sharma MC
Interdiscip Sci; 2014 Sep; 6(3):197-207. PubMed ID: 25205497
[TBL] [Abstract][Full Text] [Related]
31. Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms.
Sakaguchi K; Green M; Stock N; Reger TS; Zunic J; King C
Arch Biochem Biophys; 2004 Apr; 424(2):219-25. PubMed ID: 15047194
[TBL] [Abstract][Full Text] [Related]
32. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance.
Ekins S; Obach RS
J Pharmacol Exp Ther; 2000 Nov; 295(2):463-73. PubMed ID: 11046077
[TBL] [Abstract][Full Text] [Related]
33. Predicting Isoform-specific Binding Selectivities of Benzensulfonamides Using QSAR and 3D-QSAR.
Raskevicius V; Kairys V
Curr Comput Aided Drug Des; 2017; 13(1):75-83. PubMed ID: 27897106
[TBL] [Abstract][Full Text] [Related]
34. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4.
Kaku T; Ogura K; Nishiyama T; Ohnuma T; Muro K; Hiratsuka A
Biochem Pharmacol; 2004 Jun; 67(11):2093-102. PubMed ID: 15135306
[TBL] [Abstract][Full Text] [Related]
35. Stereochemical and steric control of the UDP-glucuronosyltransferase-catalyzed conjugation reaction: a rational approach for the design of inhibitors for the human UGT2B7.
Bichlmaier I; Finel M; Sippl W; Yli-Kauhaluoma J
ChemMedChem; 2007 Dec; 2(12):1730-40. PubMed ID: 17943712
[TBL] [Abstract][Full Text] [Related]
36. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships.
Hattotuwagama CK; Doytchinova IA; Flower DR
Methods Mol Biol; 2007; 409():227-45. PubMed ID: 18450004
[TBL] [Abstract][Full Text] [Related]
37. Identification of Human UDP-Glucuronosyltransferase 1A4 as the Major Isozyme Responsible for the Glucuronidation of 20(S)-Protopanaxadiol in Human Liver Microsomes.
Li J; He C; Fang L; Yang L; Wang Z
Int J Mol Sci; 2016 Mar; 17(3):205. PubMed ID: 27005621
[TBL] [Abstract][Full Text] [Related]
38. Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors.
Halder AK; Saha A; Jha T
J Pharm Pharmacol; 2013 Oct; 65(10):1541-54. PubMed ID: 24028622
[TBL] [Abstract][Full Text] [Related]
39. Pharmacophore modeling, 3D-QSAR and molecular docking studies of benzimidazole derivatives as potential FXR agonists.
Sindhu T; Srinivasan P
J Recept Signal Transduct Res; 2014 Aug; 34(4):241-53. PubMed ID: 25072161
[TBL] [Abstract][Full Text] [Related]
40. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
Wei HY; Lu CS; Lin TH
J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
